Training Workshop: Assessment of the Quality Part of the Dossier
Copenhagen, Denmark

January 20-22, 2010

Trip Report

Edwin Toledo, ASQ-CQA
Program Manager/GMP Specialist

Kennedy M. Chibwe, Ph.D., MBA
Senior Program Advisor

Promoting the Quality of Medicines Program
Implemented by U.S. Pharmacopeia
12601 Twinbrook Parkway
Rockville, MD 20852 USA
Tel: (+1) 301-816-8162
Fax: (+1) 301-816-8374
Email: pqm@usp.org

Cooperative Agreement # GHS-A-00-09-00003-00
Grantee: Promoting the Quality of Medicines (PQM) Program
Author(s) Name: PQM Staff
Language: English
Date of Publication: March 23, 2010

This report is made possible by the generous support of the American people through the United States Agency for International Development (USAID), under Cooperative Agreement No. GHS-A-00-09-00003-00. The contents are the responsibility of the Promoting the Quality of Medicines Program, implemented by the U. S. Pharmacopeia, and do not necessarily reflect the views of USAID or the United States Government.
About PQM
The Promoting the Quality of Medicines (PQM) program, funded by the U.S. Agency for International Development (USAID), is the successor of the Drug Quality and Information (DQI) program implemented by the United States Pharmacopeia (USP). PQM is USAID’s response to the growing challenge posed by the proliferation of counterfeit and substandard medicines. By providing technical leadership to developing countries, PQM helps build local capacity in medicine quality assurance systems, increase the supply of quality medicines to priority USAID health programs, and ensure the quality and safety of medicines globally. This document does not necessarily represent the views or opinions of USAID or the United States Government. It may be reproduced if credit is given to PQM and USP.

Abstract
PQM staff (Kennedy Chibwe and Edwin Toledo) traveled to Copenhagen, at the invitation of the World Health Organization (WHO) Prequalification Team, to participate in the Training Workshop: Assessment of the Quality Part of the Dossier. The workshop helped increase the knowledge of key dossier requirements and some commonly encountered deficiencies and how to provide better technical assistance to manufacturers interested in pursuing WHO prequalification for second-line tuberculosis (TB) drugs.

Recommended Citation

Key Words
WHO Prequalification, dossier, second-line anti-TB medicines
Table of Contents

<table>
<thead>
<tr>
<th>Acknowledgements</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acronyms</td>
<td>5</td>
</tr>
<tr>
<td>Background</td>
<td>6</td>
</tr>
<tr>
<td>Purpose of Trip.</td>
<td>6</td>
</tr>
<tr>
<td>Source of Funding</td>
<td>6</td>
</tr>
<tr>
<td>Overview of Activities</td>
<td>6</td>
</tr>
<tr>
<td>Conclusions</td>
<td>6</td>
</tr>
<tr>
<td>Annex 1: Participant List</td>
<td>8</td>
</tr>
<tr>
<td>Annex 2: Agenda</td>
<td>10</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENTS

The authors would like to thank:

- Dr. M. Stahl, Medical Officer, Head of Assessments Quality Assurance & Safety: Medicines Policy and Standards, World Health Organization (WHO)

- PQM editors and administrative staff for editing this report and assisting with logistics

- Mr. Anthony Boni and Ms. Veerle Coignez at USAID in Washington, D.C. for their support and advice
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATB</td>
<td>Anti-tuberculosis medicine</td>
</tr>
<tr>
<td>DQI</td>
<td>Drug Quality and Information Program</td>
</tr>
<tr>
<td>GDF</td>
<td>Global Drug Facility</td>
</tr>
<tr>
<td>GLC</td>
<td>Green Light Committee</td>
</tr>
<tr>
<td>GMP</td>
<td>Good Manufacturing Practices</td>
</tr>
<tr>
<td>MDR-TB</td>
<td>Multi-drug resistant tuberculosis</td>
</tr>
<tr>
<td>PQM</td>
<td>Promoting the Quality of Medicines Program</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>USAID</td>
<td>United States Agency for International Development</td>
</tr>
<tr>
<td>USP</td>
<td>United States Pharmacopeia</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
Background
Despite efforts by the WHO Prequalification program, Global Drug Facility (GDF), and the Green Light Committee (GLC) to increase access to essential anti-tuberculosis medicines (ATBs), there are not enough WHO-prequalified second-line ATBs and manufacturers available. There is also an inadequate supply of products to treat patients with multi-drug resistant TB (MDR-TB). DQI (now PQM) has been assisting GDF in its efforts to increase the availability of good quality second-line ATBs. To expedite the prequalification process and thereby expand the pool of viable manufacturers, PQM is providing technical assistance to interested companies to:

- Prepare their product dossiers for submission to the WHO prequalification program in a manner that fulfills the prequalification requirements
- Facilitate discussions with WHO to remedy incomplete dossiers or to respond to WHO comments
- Guide manufacturers onsite to comply with the principles and guidelines of WHO Good Manufacturing Practices (GMP) and the requirements of the prequalification program

Purpose of Trip
Mr. Toledo and Dr. Chibwe traveled to Copenhagen to participate in the Training Workshop: Assessment of the Quality Part of the Dossier Training to increase their knowledge of key dossier requirements and gain insight into some commonly encountered deficiencies.

Source of Funding
This trip was supported with Core funds for TB.

Overview of Activities

Training Workshop: Assessment of the Quality Part of the Dossier

January 20-22, 2010
The workshop was held in UNICEF supply division headquarters in Copenhagen, Denmark. After brief introductions by Dr. Stahl and the participants (see Annex 1 for the full list of participants), Linda Palahniuk, Wondiyfraw Worku, Satish Mallya, and Theo Dekker led the training (see Annex 2 for the agenda). The training covered background to prequalification to drug development to final medicine product. Participants were given an opportunity to review and provide solutions to different case study scenarios, and one-on-one meetings with the trainers were held on the last day of the workshop.

Presentation Materials
Presentations will be posted at http://apps.who.int/prequal/ under “Training material, workshops and meetings.”

Conclusions
Both Mr. Toledo and Dr. Chibwe found the training useful and trust this will further enhance PQM’s ability to offer timely and relevant technical assistance to manufacturers seeking to undergo the WHO prequalification process for their medicines.
Participants and Trainers
Training Workshop: Assessment of the Quality Part of the Dossier, Copenhagen, January 2010
Mr Ruteado Jethro KUWANA
Technical Officer, Prequalification of Medicines Programme
World Health Organization, Switzerland
Tel: +41 22 791 4309
e-mail: kuwanaru@who.int

Ms Seloi MOGATLE
MPharm (Hons); MSc Pharmacy (Pharmaceutics)
Principal Pharmacist I
Drugs Registration Section
Drugs Regulatory Unit
Department of Clinical Services
Ministry of Health, Botswana
Tel: 00267 3633381
e-mail: smogatle@gov.bw

Mr Hiiti SILLO
Director, Medicines and Cosmetics
Food and Drugs Authority, Tanzania
e-mail: hiiti@yahoo.com

Ms Yaowapa SRABUA
Pharmacist
Drug Control Division
Food and Drug Administration
Ministry of Public Health, Thailand
Tel: +66 2 590 7167
e-mail: yaowapua@fda.moph.go.th

Ms Ligia TEMBE
Pharmacist
Pharmaceutical Department/MISAU, Mozambique
Tel: +258 44 37 210
e-mail: ligiatembe@yahoo.com.br

Mr Edwin TOLEDO
Program Manager GMP Specialist
The United States Pharmacopoeial Convention
Tel: 1-301-816-8165
e-mail: edwintoledo@comcast.net

Dr William WEKWEWE
Assistant Director-Evaluations & Registration Unit
Medicines Control Authority of Zimbabwe
Tel: +263-4 736 701
e-mail: williamwekwe@gmail.com

Ms Alisa YEVCHENKO
Technical Officer, Prequalification of Medicines Programme
World Health Organization, Switzerland
Tel: +41 22 791 4379
e-mail: yevchenko@who.int
Participants List

Ma Mercy ACQUAYE
Regulatory Officer
Head, Medicines Evaluation and Registration
Food and Drugs Board, Ghana
Tel: +233244652336
e-mail: mercyaquaye@yahoo.com

Dr Abdullah M AL MOHIZEA
Director of Product Evaluation and Standard Setting Administration
The Saudi Food and Drug Authority, Saudi Arabia
Tel: +96 634320339
e-mail: ammohizea.c@sfda.gov.sa

Mr Tefert Lemma BEDANE
Pharmacist (B.pharm. Mac)
Drug Evaluation & Registration, Ethiopia
Tel: +251 091-636468
e-mail: tefert@yahoo.co.uk

Dr Andrew Kimutai CHEMWOLO
Head, Quality Assurance Unit
Pharmacy board, Ministry of Health, Kenya
Tel: +254 20 3562107 Ext 109 or +254 722 801822
e-mail: achemwole@yahoo.com or achemwole@pharmacyboardkenya.org

Dr Kennedy M CHIBWE
Deputy Director
Senior Program Advisor
Promoting The Quality Of Medicines Program, United States
Tel: +301-816-6158/610-510-6389
e-mail: kennedy.1228@yahoo.com and/or kmc@wsp.org

Mr Felix Peter CHIZU
Regulatory Officers/Pharmacist
Pharmaceutical Regulatory Authority, Zambia
Tel: +260 211 220 429/ +260 977 810 177
e-mail: fpchizu@pra.gov.zm or fpchizu@yahoo.co.uk
ANNEX 2

Agenda: Quality Assessment - Training Workshop January 20-22, 2010

Wednesday January 20, 2010:

8:30-8:45: Welcome and Introduction: Matthias Stahl

8:45-9:00: 1-1 Training Session Outline and Objectives: Lynda Paleshnuik

9:00-10:00 1-2 Prequalification: what it means, how it works, why we do it (the view from Geneva): Wondlyfraw Worku

10:00-10:20: Break

10:20-11:00 1-3 API Sections: Tips and Common Deficiencies: Lynda Paleshnuik

11:00-12:00: 1-4 API Specifications: Wondlyfraw Worku

12:00-13:00: Lunch

13:00-14:00 1-5 API Stability: Lynda Paleshnuik

14:00-14:20: Break

14:20-16:00 1-6 Pharmaceutical Development: Satish Mallya

16:00-17:00: Exercise on Day 1 material

Thursday January 21, 2010

8:30-8:45: Questions on Day 1 Material

8:45-10:15: 2-1 Dissolution as applied to development, specifications and biowaivers: Theo Dekker

10:15-10:35: Break

10:35-12:00: 2-2 FPP specifications: Wondlyfraw Worku

12:00-13:00: Lunch

13:00-14:30: 2-3 Process Validation: Satish Mallya

14:30-14:50: Break

14:50-16:00: 2-4 FPP Sections: Tips and Common Deficiencies: Lynda Paleshnuik

16:00-17:00: Exercise on Day 2 material

Friday January 22, 2010

8:30-8:45: Questions on Day 2 Material